Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

3244 - Regorafenib for metastatic colorectal carcinoma: a registry-based analysis

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Katerina Kopeckova

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

K. Kopeckova1, R. Chloupkova2, B. Melichar3, Z. Linke1, L.B. Petruzelka4, J. Finek5, O. Fiala6, J. Tomasek7, I. Kiss7, J. Prausova1, T. Buchler8

Author affiliations

  • 1 Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, 15006 - Prague/CZ
  • 2 Institute Of Biostatistics And Analyses, Masaryk University Brno, 62500 - Brno/CZ
  • 3 Oncology, Palacky University Medical School and Teaching Hospital, 77520 - Olomouc/CZ
  • 4 Oncology, First Faculty of Medicine, Charles University and General University Hospital, 128 08 - Prague/CZ
  • 5 Oncology, University Hospital Plzen, 30133 - Plzen/CZ
  • 6 Oncology, University Hospital Plzen, 30460 - Plzen/CZ
  • 7 Department Of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 65653 - Brno/CZ
  • 8 Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, 140 59 - Prague/CZ
More

Resources

Abstract 3244

Background

Regorafenib is a multikinase inhibitor approved for the therapy of patients with metastatic colorectal carcinoma (mCRC) previously treated with a fluoropyrimidine, oxaliplatin, irinotecan, anti-VEGF therapy, and (in wild-type RAS tumours) anti-EGFR therapy. The aim of the present study was to analyse the outcomes of treatment with regorafenib in real-world clinical practice based on data from a national registry.

Methods

The CORECT registry (http://corect.registry.cz) is a non-interventional database of patients with colorectal cancer treated with targeted agents. The analysis included 451 evaluable patients treated with regorafenib for mCRC.

Results

The median age at diagnosis was 61.1 years. The primary tumor was in the left colon or rectum in 343 patients (76.1%), right colon in 81 patients (18.0%), data on location were not available for 27 patients (6.0%). KRAS mutation was detected in 202 patients (44.8%) and NRAS mutation in 40 patients (8.9%). The median duration of treatment was 2.7 months (range 0.0-23.4 months). Partial response was seen in 12 patients (3.2%). Progression of the disease was reported in 170 patients (44.7%) and disease stabilisation for at least 6 weeks in 110 patients (28.9%). Progression-free and overall survival data are shown in the table. Improved outcomes were observed in patients with longer interval from diagnosis of mCRC and in those without liver metastases. Age, tumor sidedness, and RAS status were not associated with outcome of regorafenib therapy. The main cause of treatment discontinuation was disease progression (71.3%) followed by general deterioration in the absence of radiological progression in 93 patients (24.5%), and adverse events related to regorafenib in (4.2%).Table: 468P

Progression-free survival and overall survival of patients treated with regorafenib

Median (95% CI)3-month survival (95% CI)6-month survival (95% CI)
Progression-free survival3.5 months (3.2–3.7)57.6% (52.5–62.4)25.2% (20.9–29.9)
Overall survival9.3 months (7.9–10.7)88.8% (85.2–91.5)68.7% (63.6–73.3)

Conclusions

Overall survival of patients treated with regorafenib in real-world clinical practice exceeded that achieved in randomised trials.

Clinical trial identification

Legal entity responsible for the study

Katerina Kopeckova and Tomas Buchler.

Funding

The Institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University, Brno received financial support for the CORECT registry from Bayer, Amgen, Merck and Roche. Supported by Grant AZV 15-26535A from the Czech Health Research Council.

Editorial Acknowledgement

Disclosure

K. Kopeckova: Research support: Bayer. B. Melichar: Consulting fees: Roche, Novartis, Astellas, Bristol-Myers Squibb, MSD, Merck, Pfizer, Janssen; Travel: Roche, Novartis, Astellas, Bristol-Myers Squibb; Provision of writing assistance: Roche, Bristol-Myers Squibb Payment for lectures: Roche, Novartis, Astellas, Bristol-Myers Squibb, MSD, Merck, Pfizer, Janssen. J. Finek: Lecture honoraria, travel grants: Roche, Merck, Pfizer, Novartis, Amgen. O. Fiala, T. Buchler: Research funding, travel grants, honoraria: Roche, Merck, Bayer, Servier, BMS, MSD, Sanofi, Amgen. J. Tomasek: Grants, consulting fees, travel: Bayer. I. Kiss: Speakers’ honoraria: Roche, Merck, Amgen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings